Eliem delays a depression trial, indefinitely postpones another after blaming CMC issues for low drug exposure

In the drug R&D world, plans are not set in stone, as Eliem Therapeutics exhibited Monday with shifts to its depression strategy.

The Seattle-UK biotech …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eliem de­lays a de­pres­sion tri­al, in­def­i­nite­ly post­pones an­oth­er af­ter blam­ing CMC is­sues for low drug ex­po­sure